Global

Maude Schmidt and Giovanni Saldutti look at the intergovernmental initiatives involving joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy to explore the outcomes and implications from these alliances.

Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.

In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.

Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.

Research-based companies in Europe look as though they have lost one battle on preserving incentives for innovation – but the bigger war is only now getting underway, writes Reflector.

Behind an economic revival in Portugal, including healthcare spending growth, the nation’s life sciences sector is benefiting as well, with Portugal diverging from the European averages to show an increase in R&D and innovation.

Artificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.

With China predicted to account for 48% of the global diabetes population by 2045, Jin Zhang looks at how the country's domestic pharma companies are faring in this treatment area.

Global pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.

Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.

Filip Conic outlines the market-access approaches and commercial strategies to unlock the growth potential in the Southeastern and Eastern European region.

Exploring the prospects-and related challenges-for Chinese life science as it aggressively pursues new growth areas.

New Jersey is still a top pick for companies when it comes to pharma.

The Indian pharmaceutical industry is traditionally known as a global powerhouse for the production of bulk drugs and generics, but less heralded is the growth India has made on the pharma world stage in several other areas, including biotechnology and R&D.

Korean biotech opens first U.S. headquarters in New Jersey to better control clinical trials as it looks for strategic partnerships in the U.S.

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

China's nurse educator program aims to improve quality of care and make life simpler for physicians handling high patient load. Sebastian Bather reports.

Figuring out the workings of the EU in topics related to health can be akin to deciphering Egyptian hieroglyphs, making it challenging for companies to plan ahead, writes Reflector.

On May 1, China eliminated the tariff on 28 categories of imported drugs. Jin Zhang looks at the implications for foreign and domestic pharma companies.

Weighing the crossover effect of US’s new pricing blueprint. 

The PD-1/PD-L1 market in China is heating up and companies there have made a series of advances, writes Jin Zhang.

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.

Pair of EU meetings, while well-meant, offered little action and beg the question-what’s the true merit in working together?

Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.

Jin Zhang identifies the major domestic companies in China’s IVD industry.

Jin Zhang discusses the research and development of several major biologics in China.

Jin Zhang looks at how China's CART-T therapy race is heating up.

Looking back at the agenda of a 1985 EFPIA conference demonstrates that, three decades on, the European drug industry is still seeking a pill for its own ills.